1. Home
  2. Clinical Topics
  3. FDA approves new breast cancer treatment for patients with a specific genetic mutation
Clinical TopicsDrugs and DevicesOncologyWeb Exclusives
fda breast cancer treatment patient genetic mutation

FDA approves new breast cancer treatment for patients with a specific genetic mutation

Share

On Jan. 12, the U.S. Food and Drug Administration (FDA) expanded the approved use of Lynparza (olaparib tablets) to include the treatment of patients with certain types of breast cancer that have metastasized and whose tumors have the BRCA gene mutation, making it the first drug in its class (PARP inhibitor) approved to treat breast cancer.

Read more via Fda.gov.

Leave a Reply

Your email address will not be published.

Fill out this field
Fill out this field
Please enter a valid email address.

Get your free subscription to NurseLine!

NurseLine Newsletter

  • Hidden

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.

Recent Posts